Cardiovascular complications associated with novel agents in the chronic lymphocytic leukemia armamentarium: A pharmacovigilance analysis

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

John C. Byrd, Peter Hillmen, Paolo Ghia et al. · Journal of Clinical Oncology · 2021 · 635 citations · Full text

Medicine, Oncology, Pharmacology +10

Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice

Zhongyi Chen, Chu Chang Chua, Ye‐Shih Ho et al. · American Journal of Physiology-Heart and Circulatory Physiology · 2001 · 410 citations

Life Sciences, Cardiology, Molecular Biology +13

Hypertension and incident cardiovascular events following ibrutinib initiation

Tyler Dickerson, Tracy Wiczer, Allyson Waller et al. · Blood · 2019 · 250 citations · Full text

Medicine, Cardiology, Pharmacology +13

Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase

Ling Xiao, Joe‐Elie Salem, Alan Hanley et al. · Circulation · 2020 · 235 citations · Full text

Medicine, Cardiology, Pharmacology +17

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Anthony R. Mato, Chadi Nabhan, Paul M. Barr et al. · Blood · 2016 · 189 citations · Full text

Medicine, Oncology, Pharmacotherapy +13